MedWatch

Analyst: Slow penetration for alcohol pill

Last week’s approval of Lundbeck’s alcohol pill will not add much to company turnover this year or the next, says an analyst, who has markedly lower expectations for the drug than Lundbeck does.

“As I see it you should not expect any significant contribution from Selincro. The contribution from this drug will be very limited in 2013,” says Sydbank analyst, Søren Løntoft Hansen, following last week’s European approval of the Selincro, a pill to treat alcohol addiction.

“The drug will have a relatively slow penetration. What will have an effect in 2013 and 2014 are the costs connected with penetrating the relevant markets for the alcohol pill. It will take its toll as far as costs are concerned to launch the drug and spread the message about the benefits of the pill to doctors,” the analyst points out.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier